Key Highlights

  • Genprex enacts a 1:22 reverse stock split effective July 16, 2026, reducing outstanding shares from 11,108,577 to approximately 504,936.
  • The company’s common stock CUSIP number changes to 372446-401 while retaining the GNPX trading symbol.
  • Acclaim-1 clinical trial receives FDA Fast Track designation for REQORSA combined with AstraZeneca’s Tagrisso in NSCLC patients.
  • Investor presentation updates oncology and diabetes gene therapy programs, available on Genprex’s website.

Reverse Split Takes Effect

Genprex (NASDAQ: GNPX) will implement a 1:22 reverse stock split at market open on July 16, 2026. The move consolidates every 22 shares of common stock into one share, reducing the total outstanding from 11,108,577 to approximately 504,936. The par value of $0.001 per share remains unchanged, and the GNPX ticker symbol stays the same.

CUSIP Update Confirmed

The reverse split triggers a new CUSIP number for Genprex’s common stock, now assigned as 372446-401. Shareholders holding fractional shares will receive cash in lieu of fractional units, ensuring no investor ends up with partial ownership. The adjustment applies uniformly across all stockholders without altering proportional equity stakes.

Board Approval Timeline

Genprex’s board approved the 1:22 ratio on July 2, 2026, following stockholder authorization at the June 18 annual meeting. The approved range allowed for ratios between 1:5 and 1:50, with the final decision falling within those parameters. The filing with Delaware’s Secretary of State occurred on July 13, 2026.

Clinical Trial Progress

Genprex’s Acclaim-1 trial, a Phase 1/2 study combining REQORSA with AstraZeneca’s Tagrisso, continues enrolling patients in its Phase 2a expansion. The FDA granted Fast Track designation for the therapy in NSCLC patients who progressed after Tagrisso treatment. Early data showed prolonged progression-free survival in select Phase 1 participants.

Biomarker Breakthroughs

Recent research identified TROP-2 and PTEN proteins as potential biomarkers predicting REQORSA response. Preclinical data demonstrated higher efficacy in NSCLC cells with elevated TROP-2 or reduced PTEN levels. Genprex plans to refine enrollment criteria for the Acclaim-1 trial based on these findings before any interim analysis.

Investor Presentation Released

Genprex published an updated investor presentation on July 14, 2026, detailing advancements in oncology and diabetes gene therapy programs. The slides, available on the company’s website, include business updates and clinical trial timelines. The presentation may be used in future investor meetings with modifications.

Acclaim-3 Trial Expansion

The Acclaim-3 study, evaluating REQORSA with Genentech’s Tecentriq in small cell lung cancer, is enrolling patients in its Phase 2 expansion. The trial targets 50 participants across 10-15 U.S. Sites, focusing on progression-free survival at 18 weeks. A futility analysis will assess early efficacy signals during the Phase 2 portion.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.